Abatacept
| Evidence Level: L3 | Predicted Indications: 7 |
Table of Contents
Abatacept: T-cell co-stimulation blocker → ankylosing spondylitis
One-Sentence Summary
Abatacept is a biologic that blocks T-cell co-stimulation. The TxGNN model predicts it may be useful for ankylosing spondylitis, but the available studies are small and uncontrolled, and a published study reports lack of efficacy in axial disease. Currently 1 directly relevant pilot clinical trial and 2 directly relevant publications are available, and the evidence is mixed to negative.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | ankylosing spondylitis |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Abatacept is a fusion protein that blocks T-cell co-stimulation, and it is established in other immune-mediated joint diseases. Ankylosing spondylitis is also an immune-mediated inflammatory joint disease, so blocking T-cell activation is a plausible idea.
Clinical data do not support this idea well. A pilot open-label study and a published cohort report in axial spondyloarthropathy refractory to TNF inhibitors found no efficacy. A 2016 review also notes that T-cell-targeting biologics, including abatacept, are not effective in axial spondyloarthritis, whereas TNF blockers are highly effective. The high model score is therefore not backed by clinical results.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00558506 | Phase 2 | Unknown | 30 | Open-label pilot of intravenous abatacept in ankylosing spondylitis, up to week 30; small and uncontrolled |
| NCT01965132 | N/A | Recruiting | 10000 | Korean registry of biologic and targeted therapy safety in RA, AS and PsA; observational, not specific to abatacept |
| NCT07138898 | Phase 2 | Recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients having shoulder arthroplasty; does not assess AS efficacy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21415053 | 2011 | Open-label pilot study | Ann Rheum Dis | 24-week pilot exploring short-term efficacy and safety of abatacept in active AS |
| 21497538 | 2012 | Cohort/Open-label | Joint Bone Spine | Lack of efficacy of abatacept in axial spondyloarthropathies refractory to TNF inhibitors |
| 27856659 | 2016 | Review | Rheumatology (Oxford) | TNF blockers are highly effective in axSpA, while T-cell-targeting abatacept and other non-TNF biologics are not |
| 25488787 | 2014 | Review | Best Pract Res Clin Rheumatol | Treatment of spondyloarthritis beyond TNF-alpha blockade |
| 31171316 | 2018 | Review | Best Pract Res Clin Rheumatol | Emerging treatment options for spondyloarthritis |
| 26968522 | 2016 | Review | Pediatr Rheumatol Online J | Biologic agents in juvenile spondyloarthropathies |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 163966 | Orencia Powder for infusion | box of 1 Powder for infusion | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 73 interactions were found in the interaction database. Major ones include adalimumab, baricitinib, certolizumab pegol and live BCG vaccine. Moderate ones include anakinra, azathioprine, alemtuzumab, canakinumab, roflumilast and several live vaccines. Zinc salts are minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is very high, but the only direct studies are a small uncontrolled pilot trial and open-label reports, and a published study found no efficacy in axial disease. Established TNF inhibitors already work well in this disease.
To proceed, the following is needed:
- Results from the completed pilot trial (NCT00558506), and a controlled trial if any signal exists
- Mechanism of action data
- Package insert warnings and contraindications from the local label
- Review of the combination safety signals with TNF inhibitors and JAK inhibitors
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.